晚期肝细胞癌的前瞻性临床治疗研究

Prospective Study on Clinical Therapy of Late Hepatocellular Carcinoma

１６０ 例确诊为晚期肝细胞癌患者被随机分为Ａ、Ｂ与Ｃ 三组。Ａ 组应用特异性肿瘤细胞毒Ｔ 淋巴细胞（ ＣＴＬｓ） 加肝动脉化疗（ ＨＡＩＣ） 联合疗法；Ｂ组予ＣＴＬｓ 单一疗法；Ｃ组接受单一ＨＡＩＣ治疗。结果提示，联合疗法的总缓解率（ 完全反应＋ 部分反应） 与１ 、２ 、３ 年的生存率均比两种单一治疗高（ Ｐ＜ ０－０１） 。因此，ＣＴＬｓ 加ＨＡＩＣ联合疗法可能是治疗晚期肝细胞癌病人理想的治疗手段。

patients with late hepatocellular carcinoma were treated by specific cytotoxicity T lymphocytes (CTLS) ,hepatic arteryim munity chemotherapy (HAIC)-160 cases wererandomly divided into three groups of A-Band C-Agroup was given a singletreatment of CTLSand CHALC-Totalre mission rate (CR+ PR) andsurvivalratein 1 ,2 and 3 years with CTLS+ HALCcombinedtherapy were higherthan twosingletreatment groups( P< 0-01)-CTLsand HAICcombined therapy wasconsidered thatthistherapy may be a goodideal way to treatlate hepatocellularcarcinoma-